Hit to lead development of imidazopyridine containing compounds as treatment for babesiosis

babesiosis, the illness caused by the tickborne malaria-like parasite Babesia, is an emerging infectious disease for which existing antimicrobials are inadequate in immunocompromised hosts. There is a critical need for development of new therapeutics. A series of 28 imidazopyridine-containing compounds (ICCs) which have been identified as highly potent in vitro growth inhibitors of babesia duncani can potentially fill this need. Project Number: 5P20GM125498-08 | Fiscal Year: 2025 | NIH Institute/Center: National Institute of General Medical Sciences (NIGMS) | Principal Investigator: Peter Hyson | Institution: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, BURLINGTON, VT | Award Amount: $191,875 | Activity Code: P20 | Study Section: ZGM1-RCB-4(C2) View on NIH RePORTER: https://reporter.nih.gov/project-details/11494846